vs
Idexx Laboratories（IDXX）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
Idexx Laboratories的季度营收约是Rithm Capital Corp.的1.3倍（$1.1B vs $828.2M），Idexx Laboratories净利率更高（22.8% vs 13.2%，领先9.5%），Idexx Laboratories同比增速更快（14.3% vs -40.0%），过去两年Idexx Laboratories的营收复合增速更高（6.4% vs -17.9%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
IDXX vs RITM — 直观对比
营收规模更大
IDXX
是对方的1.3倍
$828.2M
营收增速更快
IDXX
高出54.3%
-40.0%
净利率更高
IDXX
高出9.5%
13.2%
两年增速更快
IDXX
近两年复合增速
-17.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $828.2M |
| 净利润 | $248.2M | $109.5M |
| 毛利率 | 60.3% | — |
| 营业利润率 | 28.9% | — |
| 净利率 | 22.8% | 13.2% |
| 营收同比 | 14.3% | -40.0% |
| 净利润同比 | 14.8% | 20.9% |
| 每股收益（稀释后） | $3.09 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXRITM
| Q1 26 | — | $828.2M | ||
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $998.4M | $768.4M | ||
| Q4 24 | $954.3M | $2.1B | ||
| Q3 24 | $975.5M | $619.5M | ||
| Q2 24 | $1.0B | $1.2B |
净利润IDXXRITM
| Q1 26 | — | $109.5M | ||
| Q4 25 | $248.2M | $85.0M | ||
| Q3 25 | $274.6M | $221.5M | ||
| Q2 25 | $294.0M | $311.7M | ||
| Q1 25 | $242.7M | $78.8M | ||
| Q4 24 | $216.1M | $290.2M | ||
| Q3 24 | $232.8M | $121.7M | ||
| Q2 24 | $203.3M | $235.6M |
毛利率IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.4% | — | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.7% | — |
营业利润率IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | 28.9% | 13.8% | ||
| Q3 25 | 32.1% | 21.4% | ||
| Q2 25 | 33.6% | 25.2% | ||
| Q1 25 | 31.7% | 7.4% | ||
| Q4 24 | 27.4% | 23.8% | ||
| Q3 24 | 31.2% | 7.3% | ||
| Q2 24 | 26.3% | 23.6% |
净利率IDXXRITM
| Q1 26 | — | 13.2% | ||
| Q4 25 | 22.8% | 5.7% | ||
| Q3 25 | 24.8% | 20.0% | ||
| Q2 25 | 26.5% | 25.6% | ||
| Q1 25 | 24.3% | 10.3% | ||
| Q4 24 | 22.7% | 14.0% | ||
| Q3 24 | 23.9% | 19.7% | ||
| Q2 24 | 20.3% | 19.2% |
每股收益（稀释后）IDXXRITM
| Q1 26 | — | $0.12 | ||
| Q4 25 | $3.09 | $0.09 | ||
| Q3 25 | $3.40 | $0.35 | ||
| Q2 25 | $3.63 | $0.53 | ||
| Q1 25 | $2.96 | $0.07 | ||
| Q4 24 | $2.62 | $0.50 | ||
| Q3 24 | $2.80 | $0.20 | ||
| Q2 24 | $2.44 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | — |
| 总债务越低越好 | $450.0M | — |
| 股东权益账面价值 | $1.6B | $9.1B |
| 总资产 | $3.4B | $53.4B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | $180.1M | $1.8B | ||
| Q3 25 | $208.2M | $1.6B | ||
| Q2 25 | $164.6M | $1.6B | ||
| Q1 25 | $164.0M | $1.5B | ||
| Q4 24 | $288.3M | $1.5B | ||
| Q3 24 | $308.6M | $1.6B | ||
| Q2 24 | $401.6M | $1.2B |
总债务IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | $450.0M | $35.4B | ||
| Q3 25 | — | $32.2B | ||
| Q2 25 | — | $31.2B | ||
| Q1 25 | — | $32.2B | ||
| Q4 24 | $617.8M | $32.6B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $30.1B |
股东权益IDXXRITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | $1.6B | $8.4B | ||
| Q3 25 | $1.6B | $8.5B | ||
| Q2 25 | $1.5B | $7.9B | ||
| Q1 25 | $1.4B | $7.8B | ||
| Q4 24 | $1.6B | $7.8B | ||
| Q3 24 | $1.6B | $7.7B | ||
| Q2 24 | $1.6B | $7.3B |
总资产IDXXRITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | $3.4B | $53.1B | ||
| Q3 25 | $3.4B | $47.2B | ||
| Q2 25 | $3.3B | $44.3B | ||
| Q1 25 | $3.2B | $45.3B | ||
| Q4 24 | $3.3B | $46.0B | ||
| Q3 24 | $3.4B | $42.3B | ||
| Q2 24 | $3.4B | $42.0B |
负债/权益比IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | 0.28× | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | 0.39× | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | — |
| 自由现金流经营现金流 - 资本支出 | $326.3M | — |
| 自由现金流率自由现金流/营收 | 29.9% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $1.1B | — |
8季度趋势，按日历期对齐
经营现金流IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | $355.8M | $-114.6M | ||
| Q3 25 | $402.3M | $-2.0B | ||
| Q2 25 | $185.7M | $-557.1M | ||
| Q1 25 | $238.0M | $1.4B | ||
| Q4 24 | $262.0M | $-1.8B | ||
| Q3 24 | $220.1M | $768.1M | ||
| Q2 24 | $248.3M | $-55.7M |
自由现金流IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | $326.3M | — | ||
| Q3 25 | $371.2M | — | ||
| Q2 25 | $151.6M | — | ||
| Q1 25 | $207.9M | — | ||
| Q4 24 | $232.8M | — | ||
| Q3 24 | $192.0M | — | ||
| Q2 24 | $215.0M | — |
自由现金流率IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | 29.9% | — | ||
| Q3 25 | 33.6% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 20.8% | — | ||
| Q4 24 | 24.4% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 21.4% | — |
资本支出强度IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 3.3% | — |
现金转化率IDXXRITM
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | -1.35× | ||
| Q3 25 | 1.47× | -9.22× | ||
| Q2 25 | 0.63× | -1.79× | ||
| Q1 25 | 0.98× | 18.03× | ||
| Q4 24 | 1.21× | -6.04× | ||
| Q3 24 | 0.95× | 6.31× | ||
| Q2 24 | 1.22× | -0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
